| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 |
| Sales | 3,297,870 | 2,892,570 | 3,002,060 | 3,157,460 | 2,982,730 |
| Sales Growth | +14.01% | -3.65% | -4.92% | +5.86% | +6.78% |
| Net Income | 1,354,060 | 1,124,860 | 1,118,010 | 1,368,740 | 1,016,250 |
| Net Income Growth | +20.38% | +0.61% | -18.32% | +34.69% | -3.35% |
Shionogi & CO ADR (SGIOY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Shionogi & Co., Ltd. engages in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. Shionogi & Co., Ltd. is based in Osaka, Japan.
Fiscal Year End Date: 03/31